Cancer Research Cancer Epigenetics Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hostein, I.
Right arrow Articles by Andrew Clarke, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hostein, I.
Right arrow Articles by Andrew Clarke, P.
[Cancer Research 61, 4003-4009, May 15, 2001]
© 2001 American Association for Cancer Research

Experimental Therapeutics

Inhibition of Signal Transduction by the Hsp90 Inhibitor 17-Allylamino-17-demethoxygeldanamycin Results in Cytostasis and Apoptosis1

Isabelle Hostein, David Robertson, Francesca DiStefano, Paul Workman2 and Paul Andrew Clarke

Cancer Research Campaign Centre for Cancer Therapeutics [I. H., F. D., P. W., P. A. C.] and Confocal Microscope Facility [D. R.], Institute of Cancer Research, Sutton, Surrey SM2 5NG, United Kingdom

17-Allylamino-17-demethoxygeldanamycin (17AAG) is a first-in-class heat shock protein 90 (Hsp90) molecular chaperone inhibitor to enter clinical trials. The downstream molecular and cellular consequences of Hsp90 inhibition are not well defined. 17AAG has shown activity against human colon cancer in cell culture and xenograft models. In this study, we demonstrated that in addition to depleting c-Raf-1 and inhibiting ERK-1/2 phosphorylation in human colon adenocarcinoma cells, 17AAG also depleted N-ras, Ki-ras, and c-Akt and inhibited phosphorylation of c-Akt. A consequence of these events was the induction of cell line-dependent cytostasis and apoptosis, although the latter did not result from dephosphorylation of proapoptotic Bad. One cell line, KM12, did not exhibit apoptosis and in contrast to the other cell lines overexpressed Bag-1, but did not express Bax. Taken together with other determinants of 17AAG sensitivity, these results should contribute to a more complete understanding of the molecular pharmacology of 17AAG, which in turn should aid the future rational clinical development and use of the drug in colon and other tumor types.




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
J. R. Pritchard, B. D. Cosgrove, M. T. Hemann, L. G. Griffith, J. R. Wands, and D. A. Lauffenburger
Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death
Mol. Cancer Ther., August 1, 2009; 8(8): 2183 - 2192.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
C. MOSER, S. A. LANG, and O. STOELTZING
Heat-shock Protein 90 (Hsp90) as a Molecular Target for Therapy of Gastrointestinal Cancer
Anticancer Res, June 1, 2009; 29(6): 2031 - 2042.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. P. Semighini and J. Heitman
Dynamic duo takes down fungal villains
PNAS, March 3, 2009; 106(9): 2971 - 2972.
[Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
C. M.-E. Sauvageot, J. L. Weatherbee, S. Kesari, S. E. Winters, J. Barnes, J. Dellagatta, N. R. Ramakrishna, C. D. Stiles, A. L.-J. Kung, M. W. Kieran, et al.
Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells
Neuro-oncol, January 1, 2009; 11(2): 109 - 121.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. N. Tse, D. S. Klimstra, M. Gonen, M. Shah, T. Sheikh, R. Sikorski, R. Carvajal, J. Mui, C. Tipian, E. O'Reilly, et al.
A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors
Clin. Cancer Res., October 15, 2008; 14(20): 6704 - 6711.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Shimamura, D. Li, H. Ji, H. J. Haringsma, E. Liniker, C. L. Borgman, A. M. Lowell, Y. Minami, K. McNamara, S. A. Perera, et al.
Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance
Cancer Res., July 15, 2008; 68(14): 5827 - 5838.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. A. Eccles, A. Massey, F. I. Raynaud, S. Y. Sharp, G. Box, M. Valenti, L. Patterson, A. de Haven Brandon, S. Gowan, F. Boxall, et al.
NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis
Cancer Res., April 15, 2008; 68(8): 2850 - 2860.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
X. Cao, M. Bloomston, T. Zhang, W. L. Frankel, G. Jia, B. Wang, N. C. Hall, R. M. Koch, H. Cheng, M. V. Knopp, et al.
Synergistic Antipancreatic Tumor Effect by Simultaneously Targeting Hypoxic Cancer Cells With HSP90 Inhibitor and Glycolysis Inhibitor
Clin. Cancer Res., March 15, 2008; 14(6): 1831 - 1839.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. L. Holmes, S. Y. Sharp, S. Hobbs, and P. Workman
Silencing of HSP90 Cochaperone AHA1 Expression Decreases Client Protein Activation and Increases Cellular Sensitivity to the HSP90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin
Cancer Res., February 15, 2008; 68(4): 1188 - 1197.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Faingold, J.-C. Marshall, E. Antecka, S. Di Cesare, A. N. Odashiro, S. Bakalian, B. F. Fernandes, and M. N. Burnier Jr.
Immune Expression and Inhibition of Heat Shock Protein 90 in Uveal Melanoma
Clin. Cancer Res., February 1, 2008; 14(3): 847 - 855.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. Rixe and T. Fojo
Is Cell Death a Critical End Point for Anticancer Therapies or Is Cytostasis Sufficient?
Clin. Cancer Res., December 15, 2007; 13(24): 7280 - 7287.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
Yuhong Du, K. Moulick, A. Rodina, J. Aguirre, S. Felts, R. Dingledine, Haian Fu, and G. Chiosis
High-Throughput Screening Fluorescence Polarization Assay for Tumor-Specific Hsp90
J Biomol Screen, October 1, 2007; 12(7): 915 - 924.
[Abstract] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Y. Sharp, C. Prodromou, K. Boxall, M. V. Powers, J. L. Holmes, G. Box, T. P. Matthews, K.-M. J. Cheung, A. Kalusa, K. James, et al.
Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues
Mol. Cancer Ther., April 1, 2007; 6(4): 1198 - 1211.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Y. Sharp, K. Boxall, M. Rowlands, C. Prodromou, S. M. Roe, A. Maloney, M. Powers, P. A. Clarke, G. Box, S. Sanderson, et al.
In vitro Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors
Cancer Res., March 1, 2007; 67(5): 2206 - 2216.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Hardcastle, P. Tomlin, C. Norris, J. Richards, M. Cordwell, K. Boxall, M. Rowlands, K. Jones, I. Collins, E. McDonald, et al.
A duplexed phenotypic screen for the simultaneous detection of inhibitors of the molecular chaperone heat shock protein 90 and modulators of cellular acetylation
Mol. Cancer Ther., March 1, 2007; 6(3): 1112 - 1122.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
M. V Powers and P. Workman
Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors
Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S125 - S135.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
W. Guo, P. Reigan, D. Siegel, J. Zirrolli, D. Gustafson, and D. Ross
The Bioreduction of a Series of Benzoquinone Ansamycins by NAD(P)H:Quinone Oxidoreductase 1 to More Potent Heat Shock Protein 90 Inhibitors, the Hydroquinone Ansamycins
Mol. Pharmacol., October 1, 2006; 70(4): 1194 - 1203.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
N. F. Smith, A. Hayes, K. James, B. P. Nutley, E. McDonald, A. Henley, B. Dymock, M. J. Drysdale, F. I. Raynaud, and P. Workman
Preclinical pharmacokinetics and metabolism of a novel diaryl pyrazole resorcinol series of heat shock protein 90 inhibitors.
Mol. Cancer Ther., June 1, 2006; 5(6): 1628 - 1637.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
N. Sain, B. Krishnan, M. G. Ormerod, A. De Rienzo, W. M. Liu, S. B. Kaye, P. Workman, and A. L. Jackman
Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT
Mol. Cancer Ther., May 1, 2006; 5(5): 1197 - 1208.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
S. A. Compton, L. W. Elmore, K. Haydu, C. K. Jackson-Cook, and S. E. Holt
Induction of Nitric Oxide Synthase-Dependent Telomere Shortening after Functional Inhibition of Hsp90 in Human Tumor Cells
Mol. Cell. Biol., February 15, 2006; 26(4): 1452 - 1462.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Zaarur, V. L. Gabai, J. A. Porco Jr., S. Calderwood, and M. Y. Sherman
Targeting Heat Shock Response to Sensitize Cancer Cells to Proteasome and Hsp90 Inhibitors
Cancer Res., February 1, 2006; 66(3): 1783 - 1791.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
F. Paduano, R. Villa, M. Pennati, M. Folini, M. Binda, M. G. Daidone, and N. Zaffaroni
Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells
Mol. Cancer Ther., January 1, 2006; 5(1): 179 - 186.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Beloueche-Babari, L. E. Jackson, N. M.S. Al-Saffar, S. A. Eccles, F. I. Raynaud, P. Workman, M. O. Leach, and S. M. Ronen
Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells
Mol. Cancer Ther., January 1, 2006; 5(1): 187 - 196.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
U. Banerji, M. Walton, F. Raynaud, R. Grimshaw, L. Kelland, M. Valenti, I. Judson, and P. Workman
Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft Models
Clin. Cancer Res., October 1, 2005; 11(19): 7023 - 7032.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Bali, M. Pranpat, R. Swaby, W. Fiskus, H. Yamaguchi, M. Balasis, K. Rocha, H.-G. Wang, V. Richon, and K. Bhalla
Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2
Clin. Cancer Res., September 1, 2005; 11(17): 6382 - 6389.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Shimamura, A. M. Lowell, J. A. Engelman, and G. I. Shapiro
Epidermal Growth Factor Receptors Harboring Kinase Domain Mutations Associate with the Heat Shock Protein 90 Chaperone and Are Destabilized following Exposure to Geldanamycins
Cancer Res., July 15, 2005; 65(14): 6401 - 6408.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. A. Mesa, D. Loegering, H. L. Powell, K. Flatten, S. J. H. Arlander, N. T. Dai, M. P. Heldebrant, B. T. Vroman, B. D. Smith, J. E. Karp, et al.
Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine
Blood, July 1, 2005; 106(1): 318 - 327.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
U. Banerji, A. O'Donnell, M. Scurr, S. Pacey, S. Stapleton, Y. Asad, L. Simmons, A. Maloney, F. Raynaud, M. Campbell, et al.
Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies
J. Clin. Oncol., June 20, 2005; 23(18): 4152 - 4161.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
X. Yin, H. Zhang, F. Burrows, L. Zhang, and C. G. Shores
Potent Activity of a Novel Dimeric Heat Shock Protein 90 Inhibitor against Head and Neck Squamous Cell Carcinoma In vitro and In vivo
Clin. Cancer Res., May 15, 2005; 11(10): 3889 - 3896.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. K. Ramanathan, D. L. Trump, J. L. Eiseman, C. P. Belani, S. S. Agarwala, E. G. Zuhowski, J. Lan, D. M. Potter, S. P. Ivy, S. Ramalingam, et al.
Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients with Refractory Advanced Cancers
Clin. Cancer Res., May 1, 2005; 11(9): 3385 - 3391.
[Abstract] [Full Text] [PDF]

Home page
 Cold Spring Harb Symp Quant BiolHome page
P. WORKMAN
Drugging the Cancer Kinome: Progress and Challenges in Developing Personalized Molecular Cancer Therapeutics
Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 499 - 515.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
E. E. A. Bull, H. Dote, K. J. Brady, W. E. Burgan, D. J. Carter, M. A. Cerra, K. A. Oswald, M. G. Hollingshead, K. Camphausen, and P. J. Tofilon
Enhanced Tumor Cell Radiosensitivity and Abrogation of G2 and S Phase Arrest by the Hsp90 Inhibitor 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin
Clin. Cancer Res., December 1, 2004; 10(23): 8077 - 8084.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. de Carcer
Heat Shock Protein 90 Regulates the Metaphase-Anaphase Transition in a Polo-Like Kinase-Dependent Manner
Cancer Res., August 1, 2004; 64(15): 5106 - 5112.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. Bagatell and L. Whitesell
Altered Hsp90 function in cancer: A unique therapeutic opportunity
Mol. Cancer Ther., August 1, 2004; 3(8): 1021 - 1030.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Braga-Basaria, E. Hardy, R. Gottfried, K. D. Burman, M. Saji, and M. D. Ringel
17-Allylamino-17-Demethoxygeldanamycin Activity against Thyroid Cancer Cell Lines Correlates with Heat Shock Protein 90 Levels
J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2982 - 2988.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
I. A. Vasilevskaya, T. V. Rakitina, and P. J. O'Dwyer
Quantitative Effects on c-Jun N-Terminal Protein Kinase Signaling Determine Synergistic Interaction of Cisplatin and 17-Allylamino-17-Demethoxygeldanamycin in Colon Cancer Cell Lines
Mol. Pharmacol., January 1, 2004; 65(1): 235 - 243.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. J. H. Arlander, A. K. Eapen, B. T. Vroman, R. J. McDonald, D. O. Toft, and L. M. Karnitz
Hsp90 Inhibition Depletes Chk1 and Sensitizes Tumor Cells to Replication Stress
J. Biol. Chem., December 26, 2003; 278(52): 52572 - 52577.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J.-M. Wu, L. Xiao, X.-K. Cheng, L.-X. Cui, N.-H. Wu, and Y.-F. Shen
PKC{epsilon} Is a Unique Regulator for hsp90{beta} Gene in Heat Shock Response
J. Biol. Chem., December 19, 2003; 278(51): 51143 - 51149.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Blank, M. Mandel, Y. Keisari, D. Meruelo, and G. Lavie
Enhanced Ubiquitinylation of Heat Shock Protein 90 as a Potential Mechanism for Mitotic Cell Death in Cancer Cells Induced with Hypericin
Cancer Res., December 1, 2003; 63(23): 8241 - 8247.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
B M Seddon and P Workman
The role of functional and molecular imaging in cancer drug discovery and development
Br. J. Radiol., December 1, 2003; 76(suppl_2): S128 - S138.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
Y.-L. Chung, H. Troy, U. Banerji, L. E. Jackson, M. I. Walton, M. Stubbs, J. R. Griffiths, I. R. Judson, M. O. Leach, P. Workman, et al.
Magnetic Resonance Spectroscopic Pharmacodynamic Markers of the Heat Shock Protein 90 Inhibitor 17-Allylamino,17-Demethoxygeldanamycin (17AAG) in Human Colon Cancer Models
J Natl Cancer Inst, November 5, 2003; 95(21): 1624 - 1633.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. Fuino, P. Bali, S. Wittmann, S. Donapaty, F. Guo, H. Yamaguchi, H.-G. Wang, P. Atadja, and K. Bhalla
Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B
Mol. Cancer Ther., October 1, 2003; 2(10): 971 - 984.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Q. Yao, R. Nishiuchi, Q. Li, A. R. Kumar, W. A. Hudson, and J. H. Kersey
FLT3 Expressing Leukemias Are Selectively Sensitive to Inhibitors of the Molecular Chaperone Heat Shock Protein 90 through Destabilization of Signal Transduction-Associated Kinases
Clin. Cancer Res., October 1, 2003; 9(12): 4483 - 4493.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. S. Russell, W. Burgan, K. A. Oswald, K. Camphausen, and P. J. Tofilon
Enhanced Cell Killing Induced by the Combination of Radiation and the Heat Shock Protein 90 Inhibitor 17-Allylamino-17- Demethoxygeldanamycin: A Multitarget Approach to Radiosensitization
Clin. Cancer Res., September 1, 2003; 9(10): 3749 - 3755.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
W. Jia, C. Yu, M. Rahmani, G. Krystal, E. A. Sausville, P. Dent, and S. Grant
Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways
Blood, September 1, 2003; 102(5): 1824 - 1832.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. P. Goetz, D. O. Toft, M. M. Ames, and C. Erlichman
The Hsp90 chaperone complex as a novel target for cancer therapy
Ann. Onc., August 1, 2003; 14(8): 1169 - 1176.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Calabrese, A. Frank, K. Maclean, and R. Gilbertson
Medulloblastoma Sensitivity to 17-Allylamino-17-demethoxygeldanamycin Requires MEK/ERK
J. Biol. Chem., July 4, 2003; 278(27): 24951 - 24959.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J.-W. Park, M. W. Yeh, M. G. Wong, M. Lobo, W. C. Hyun, Q.-Y. Duh, and O. H. Clark
The Heat Shock Protein 90-Binding Geldanamycin Inhibits Cancer Cell Proliferation, Down-Regulates Oncoproteins, and Inhibits Epidermal Growth Factor-Induced Invasion in Thyroid Cancer Cell Lines
J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3346 - 3353.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. Nimmanapalli, E. O'Bryan, D. Kuhn, H. Yamaguchi, H.-G. Wang, and K. N. Bhalla
Regulation of 17-AAG--induced apoptosis: role of Bcl-2, Bcl-xL, and Bax downstream of 17-AAG--mediated down-regulation of Akt, Raf-1, and Src kinases
Blood, July 1, 2003; 102(1): 269 - 275.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. A. Vasilevskaya, T. V. Rakitina, and P. J. O'Dwyer
Geldanamycin and its 17-Allylamino-17-Demethoxy Analogue Antagonize the Action of Cisplatin in Human Colon Adenocarcinoma Cells: Differential Caspase Activation as a Basis for Interaction
Cancer Res., June 15, 2003; 63(12): 3241 - 3246.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
R. Villa, M. Folini, C. D. Porta, A. Valentini, M. Pennati, M. G. Daidone, and N. Zaffaroni
Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells
Carcinogenesis, May 1, 2003; 24(5): 851 - 859.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
G. Chiosis, H. Huezo, N. Rosen, E. Mimnaugh, L. Whitesell, and L. Neckers
17AAG: Low Target Binding Affinity and Potent Cell Activity--Finding an Explanation
Mol. Cancer Ther., February 1, 2003; 2(2): 123 - 129.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P. Workman
Auditing the Pharmacological Accounts for Hsp90 Molecular Chaperone Inhibitors: Unfolding the Relationship between Pharmacokinetics and Pharmacodynamics
Mol. Cancer Ther., February 1, 2003; 2(2): 131 - 138.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. D. Basso, D. B. Solit, G. Chiosis, B. Giri, P. Tsichlis, and N. Rosen
Akt Forms an Intracellular Complex with Heat Shock Protein 90 (Hsp90) and Cdc37 and Is Destabilized by Inhibitors of Hsp90 Function
J. Biol. Chem., October 11, 2002; 277(42): 39858 - 39866.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. S. Isaacs, Y.-J. Jung, E. G. Mimnaugh, A. Martinez, F. Cuttitta, and L. M. Neckers
Hsp90 Regulates a von Hippel Lindau-independent Hypoxia-inducible Factor-1alpha -degradative Pathway
J. Biol. Chem., August 9, 2002; 277(33): 29936 - 29944.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Neckers
Heat Shock Protein 90 Inhibition by 17-Allylamino-17- demethoxygeldanamycin: A Novel Therapeutic Approach for Treating Hormone-refractory Prostate Cancer : Commentary re: D. B. Solit et al., 17-Allylamino-17-demethoxygeldanamycin Induces the Degradation of Androgen Receptor and Her-2/neu and Inhibits the Growth of Prostate Cancer Xenografts. Clin. Cancer Res., 8: 986-993, 2002.
Clin. Cancer Res., May 1, 2002; 8(5): 962 - 966.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
X. Yu, Z. S. Guo, M. G. Marcu, L. Neckers, D. M. Nguyen, G. A. Chen, and D. S. Schrump
Modulation of p53, ErbB1, ErbB2, and Raf-1 Expression in Lung Cancer Cells by Depsipeptide FR901228
J Natl Cancer Inst, April 3, 2002; 94(7): 504 - 513.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Fujita, S. Sato, A. Ishida, and T. Tsuruo
Involvement of Hsp90 in Signaling and Stability of 3-Phosphoinositide-dependent Kinase-1
J. Biol. Chem., March 15, 2002; 277(12): 10346 - 10353.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
D. G. Stupack and D. A. Cheresh
Get a ligand, get a life: integrins, signaling and cell survival
J. Cell Sci., January 10, 2002; 115(19): 3729 - 3738.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.